For the quarter ended January 31, 2026, HeartSciences reported no meaningful product revenue while holding $3.4 million in cash and cash equivalents and $2.7 million in shareholders’ equity. The company’s financial position reflects ongoing investment in its technology platforms rather than sales of existing products.

MyoVista Insights is classified as a Medical Device Data System (MDDS), enabling faster, lower-cost rollout without 510(k) clearance. On March 13, 2026, the company released a major version upgrade featuring mobile viewing, enhanced reporting and improved interoperability ahead of its exhibit at the ACC Annual Scientific Session. Early reference installations and hospital network endorsements have generated positive feedback, and management expects to announce several key customer wins this year.

In December 2025 HeartSciences submitted its MyoVista wavECG device for FDA 510(k) premarket clearance, marking a significant regulatory milestone. The company opted to file separate submissions for its ECG device and AI-based cardiac relaxation algorithm following updated guidance on left ventricular diastolic dysfunction assessment.

HeartSciences aims to establish key reference sites and commence SaaS revenue generation from MyoVista Insights during 2026. The platform’s architecture supports an AI-ECG marketplace to host third-party algorithms alongside in-house solutions, positioning the company to tap into a multi-billion-dollar market opportunity and streamline algorithm development and regulatory pathways.